Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.
about
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeHealth-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age populationRegional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB)Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD.Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational studyDifferences in the use of spirometry between rural and urban primary care centers in Spain.Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50-64 years, the SCAPIS Pilot Study.New scoring system for the differentiation of chronic obstructive pulmonary disease and asthma.Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.Integrating COPD care in Italy.Asthma-COPD Overlap Shows Favorable Clinical Outcomes Compared to Pure COPD in a Korean COPD Cohort.Variability in objective and subjective measures affects baseline values in studies of patients with COPD.Bronchodilator response of advanced lung function parameters depending on COPD severityClinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma.Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes.Determinants of use of the bronchodilator test in primary and secondary care: results of a national survey in Spain.
P2860
Q26801134-4FC0590D-CFD3-49AD-9947-A6A8DBEB99BCQ28392181-253E4882-ACF8-48D2-81A5-0E9E284B0759Q28654249-F2A8B055-52FE-42C4-B0A8-BD1137FB256EQ31042074-5382F2F6-63B3-48E1-A76F-30CD41F37E1EQ33552577-4273D74E-4D79-4062-B888-D81E6C8BB90DQ33742510-469C5446-C223-4463-9239-E220F45218EFQ35011666-BADFE7C6-7C69-450F-AFB1-1C171D0F9C40Q35981392-3EFE7DC3-6A32-4513-B15F-1934F4006C5EQ36636050-3C102E76-C48D-466D-98FC-D673D643FD7BQ37530843-A37066C0-1978-49BA-BB0F-E3C7CA1710B5Q37615959-9368C966-514E-491E-9D65-EEAA072AD504Q37722887-C4ECDD3D-2DFF-48F9-BAF2-CC5E7D7B484CQ38427480-57AFF8E7-C244-4451-A339-7381B536A34AQ39437180-86D43631-C653-40EA-BEC8-3A4D74E6545BQ40468317-A3F98D4F-01C9-4E29-B798-2DB0B93F06DCQ40955364-DA678A79-477D-4D6F-86D1-AA5E93FAC4EFQ41828837-4ECFF74A-F5FC-4971-A332-49F872A978C5Q42060133-80E58702-78E7-44DF-9976-9BB30545BA10Q42358548-36DA367B-6161-4701-9B67-74EF5C1844F3Q49521857-0002DCF6-DBCB-47E4-B1E7-6B7025D7394CQ51700054-94655E9E-0CAA-41C8-BF41-851A97B37911
P2860
Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bronchodilator reversibility i ...... disease: use and limitations.
@en
type
label
Bronchodilator reversibility i ...... disease: use and limitations.
@en
prefLabel
Bronchodilator reversibility i ...... disease: use and limitations.
@en
P2093
P1476
Bronchodilator reversibility i ...... disease: use and limitations.
@en
P2093
Paul Albert
Paul P Walker
Peter M A Calverley
P304
P356
10.1016/S2213-2600(13)70086-9
P577
2013-06-18T00:00:00Z